BioTech IP Review

Small-molecule inhibitor of the JAK family of kinases

Assignee: Janssen Pharmaceutica NV (a Johnson & Johnson subsidiary)
Inventors: Edward F. Attiyeh, Kurtis E. Bachman, Gerald C. Chu, Tatiana Koudriakova, David C. Polidori, Gary V. Borzillo
Filed: March 9, 2022
Patent Granted: August 19, 2025
Publication Number: US20220288041

What It Covers

This patent covers a novel class of small-molecule inhibitors targeting the JAK (Janus kinase) family of tyrosine kinases — enzymes that play critical roles in inflammatory and immune-mediated diseases such as rheumatoid arthritis, ulcerative colitis, and other autoimmune disorders.

  • Chemical Composition: It claims specific small-molecule chemical structures that bind to and inhibit one or more members of the JAK family, which includes JAK1, JAK2, JAK3, and TYK2.
  • Selective Inhibition: The patented compounds are designed to differentially inhibit JAK signaling, aiming to balance efficacy against inflammatory pathways with a safer side-effect profile compared to earlier JAK inhibitors.
  • Therapeutic Methods: In addition to the chemical compositions, the patent includes methods of treatment using these molecules to manage chronic immune-mediated diseases by administering effective doses that modulate cytokine signaling through JAK inhibition.
  • Pharmaceutical Formulations: It also covers formulation aspects — how these inhibitors can be delivered (e.g., orally) and potentially combined with other agents to enhance therapeutic benefit.

Why This Patent Is Important

  1. Strategic in Inflammation & Immunology:
    — J&J already markets treatments in autoimmune and inflammatory diseases. A proprietary, next-generation JAK inhibitor family can strengthen or replace older therapies in high-revenue markets such as rheumatoid arthritis, ulcerative colitis, and psoriasis — collectively worth billions annually.
  2. Defensive IP Positioning:
    — With many competitors (e.g., Pfizer’s Xeljanz, AbbVie’s Rinvoq) in the JAK inhibitor space, owning strong composition-of-matter and use patents gives J&J (via Janssen) market exclusivity and leverage against generics or biosimilars.
  3. Long-Term Revenue Protection:
    — By securing patent protection on novel molecules (beyond existing JAK drugs already on the market), J&J can extend lifecycle value in core therapeutic areas where patents are expiring or under pressure. This is especially crucial in a year where many blockbusters face cliff events.
  4. Platform for Further Innovation:
    — These JAK inhibitors can serve as platform compounds for derivative drug development, combination therapies, or personalized approaches in immunology and oncology, increasing their commercial utility.

Summary

U.S. Patent No. 12,390,451 B2 to Janssen Pharmaceutica NV (a unit of Johnson & Johnson) — protects a new class of small-molecule JAK kinase inhibitors and related treatment methods for immune and inflammatory diseases. This patent is valuable because it expands J&J’s intellectual property in a high-growth therapeutic area, potentially enabling new drugs with improved efficacy/safety and prolonging market exclusivity amid a crowded competitive landscape.

Leave a comment